Business and Finance

The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

Deal gives Incyte access to Escient’s pipeline of oral MRGPR antagonists, including EP262 and EP547.

Company also purchased equipment for 12 good manufacturing practice clean rooms.

Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials.

Cohort study examines the potential for spending to significantly decrease for individuals who use these generic versions of biologics.

Analysis determines the suggested value of medications for diabetes if they were closer to production costs.

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications.

The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

This financial toxicity is quite prominent, but what can be done to remedy treatment costs?

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection.

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.

A Carrum Health/PWC report surveys benefit managers spanning various self-insured employers in an effort to determine ways to improve the cancer treatment experience, especially from a cost perspective.

A cross-sectional study investigates how this supply chain link helps increase Medicare Part D spending on self-administered specialty drugs.

The annual report published by IQVIA examines movement surrounding drug launches and new clinical trials, during the post-pandemic era.

As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.

The financial commitment features construction of new warehouses in Pennsylvania and North Carolina.

The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.

Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.

According to AbbVie, ImmunoGen's entire oncology portfolio could drive long-term revenue growth, giving the company a potential multi-billion dollar drug that is already on the market.

Technavio analysis notes that an increase drug patent expirations could be a contributing factor.

The acquisition expands Merck’s portfolio in the veterinary pharma space.

The deal is expected to help boost supply of Wegovy.

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.